000132541 001__ 132541
000132541 005__ 20240228135110.0
000132541 0247_ $$2doi$$a10.1016/j.ccr.2014.05.005
000132541 0247_ $$2pmid$$apmid:24954133
000132541 0247_ $$2pmc$$apmc:PMC4441014
000132541 0247_ $$2ISSN$$a1535-6108
000132541 0247_ $$2ISSN$$a1878-3686
000132541 0247_ $$2altmetric$$aaltmetric:2449834
000132541 037__ $$aDKFZ-2018-00223
000132541 041__ $$aeng
000132541 082__ $$a610
000132541 1001_ $$aVanner, Robert J$$b0
000132541 245__ $$aQuiescent sox2(+) cells drive hierarchical growth and relapse in sonic hedgehog subgroup medulloblastoma.
000132541 260__ $$aCambridge, Mass.$$bCell Press$$c2014
000132541 3367_ $$2DRIVER$$aarticle
000132541 3367_ $$2DataCite$$aOutput Types/Journal article
000132541 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1520341977_24409
000132541 3367_ $$2BibTeX$$aARTICLE
000132541 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000132541 3367_ $$00$$2EndNote$$aJournal Article
000132541 520__ $$aFunctional heterogeneity within tumors presents a significant therapeutic challenge. Here we show that quiescent, therapy-resistant Sox2(+) cells propagate sonic hedgehog subgroup medulloblastoma by a mechanism that mirrors a neurogenic program. Rare Sox2(+) cells produce rapidly cycling doublecortin(+) progenitors that, together with their postmitotic progeny expressing NeuN, comprise tumor bulk. Sox2(+) cells are enriched following anti-mitotic chemotherapy and Smoothened inhibition, creating a reservoir for tumor regrowth. Lineage traces from Sox2(+) cells increase following treatment, suggesting that this population is responsible for relapse. Targeting Sox2(+) cells with the antineoplastic mithramycin abrogated tumor growth. Addressing functional heterogeneity and eliminating Sox2(+) cells presents a promising therapeutic paradigm for treatment of sonic hedgehog subgroup medulloblastoma.
000132541 536__ $$0G:(DE-HGF)POF3-312$$a312 - Functional and structural genomics (POF3-312)$$cPOF3-312$$fPOF III$$x0
000132541 588__ $$aDataset connected to CrossRef, PubMed,
000132541 650_7 $$2NLM Chemicals$$aAntigens, Nuclear
000132541 650_7 $$2NLM Chemicals$$aAntineoplastic Agents
000132541 650_7 $$2NLM Chemicals$$aBiomarkers, Tumor
000132541 650_7 $$2NLM Chemicals$$aHedgehog Proteins
000132541 650_7 $$2NLM Chemicals$$aMicrotubule-Associated Proteins
000132541 650_7 $$2NLM Chemicals$$aNerve Tissue Proteins
000132541 650_7 $$2NLM Chemicals$$aNeuN protein, mouse
000132541 650_7 $$2NLM Chemicals$$aNeuropeptides
000132541 650_7 $$2NLM Chemicals$$aNuclear Proteins
000132541 650_7 $$2NLM Chemicals$$aPatched Receptors
000132541 650_7 $$2NLM Chemicals$$aReceptors, Cell Surface
000132541 650_7 $$2NLM Chemicals$$aReceptors, G-Protein-Coupled
000132541 650_7 $$2NLM Chemicals$$aSHH protein, human
000132541 650_7 $$2NLM Chemicals$$aSMO protein, human
000132541 650_7 $$2NLM Chemicals$$aSOX2 protein, human
000132541 650_7 $$2NLM Chemicals$$aSOXB1 Transcription Factors
000132541 650_7 $$2NLM Chemicals$$aShh protein, mouse
000132541 650_7 $$2NLM Chemicals$$aSmo protein, mouse
000132541 650_7 $$2NLM Chemicals$$aSmoothened Receptor
000132541 650_7 $$2NLM Chemicals$$aSox2 protein, mouse
000132541 650_7 $$2NLM Chemicals$$adoublecortin protein
000132541 650_7 $$2NLM Chemicals$$aneuronal nuclear antigen NeuN, human
000132541 650_7 $$0NIJ123W41V$$2NLM Chemicals$$aPlicamycin
000132541 7001_ $$aRemke, Marc$$b1
000132541 7001_ $$aGallo, Marco$$b2
000132541 7001_ $$aSelvadurai, Hayden J$$b3
000132541 7001_ $$aCoutinho, Fiona$$b4
000132541 7001_ $$aLee, Lilian$$b5
000132541 7001_ $$aKushida, Michelle$$b6
000132541 7001_ $$aHead, Renee$$b7
000132541 7001_ $$aMorrissy, Sorana$$b8
000132541 7001_ $$aZhu, Xueming$$b9
000132541 7001_ $$aAviv, Tzvi$$b10
000132541 7001_ $$aVoisin, Veronique$$b11
000132541 7001_ $$aClarke, Ian D$$b12
000132541 7001_ $$aLi, Yisu$$b13
000132541 7001_ $$aMungall, Andrew J$$b14
000132541 7001_ $$aMoore, Richard A$$b15
000132541 7001_ $$aMa, Yussanne$$b16
000132541 7001_ $$aJones, Steven J M$$b17
000132541 7001_ $$aMarra, Marco A$$b18
000132541 7001_ $$aMalkin, David$$b19
000132541 7001_ $$0P:(DE-HGF)0$$aNorthcott, Paul A$$b20
000132541 7001_ $$0P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8$$aKool, Marcel$$b21$$udkfz
000132541 7001_ $$0P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aPfister, Stefan$$b22$$udkfz
000132541 7001_ $$aBader, Gary$$b23
000132541 7001_ $$aHochedlinger, Konrad$$b24
000132541 7001_ $$0P:(DE-He78)8d9c904a6cea14d4c99c78ba46e41f93$$aKorshunov, Andrey$$b25$$udkfz
000132541 7001_ $$aTaylor, Michael D$$b26
000132541 7001_ $$aDirks, Peter B$$b27
000132541 773__ $$0PERI:(DE-600)2074034-7$$a10.1016/j.ccr.2014.05.005$$gVol. 26, no. 1, p. 33 - 47$$n1$$p33 - 47$$tCancer cell$$v26$$x1535-6108$$y2014
000132541 909CO $$ooai:inrepo02.dkfz.de:132541$$pVDB
000132541 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8$$aDeutsches Krebsforschungszentrum$$b21$$kDKFZ
000132541 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aDeutsches Krebsforschungszentrum$$b22$$kDKFZ
000132541 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8d9c904a6cea14d4c99c78ba46e41f93$$aDeutsches Krebsforschungszentrum$$b25$$kDKFZ
000132541 9131_ $$0G:(DE-HGF)POF3-312$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunctional and structural genomics$$x0
000132541 9141_ $$y2014
000132541 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCER CELL : 2015
000132541 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000132541 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000132541 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000132541 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000132541 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000132541 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000132541 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000132541 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000132541 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000132541 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000132541 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000132541 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000132541 915__ $$0StatID:(DE-HGF)9920$$2StatID$$aIF >= 20$$bCANCER CELL : 2015
000132541 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lPädiatrische Neuroonkologie$$x0
000132541 9201_ $$0I:(DE-He78)G380-20160331$$kG380$$lKKE Neuropathologie$$x1
000132541 980__ $$ajournal
000132541 980__ $$aVDB
000132541 980__ $$aI:(DE-He78)B062-20160331
000132541 980__ $$aI:(DE-He78)G380-20160331
000132541 980__ $$aUNRESTRICTED